Critical considerations in the formulation development of parenteral biologic drugs.

Clicks: 384
ID: 79605
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 7 articles by views in Drug discovery today

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Biopharmaceuticals, unlike chemically synthesized small-molecule drugs, are marginally stable, with most of them requiring 3D structures to retain their activity and/or potency. This implies challenges to formulate these molecules for a shelf life >2 y of and also to minimize the cost of goods for manufacturing. Patient compliance has become a key consideration in the design and development of suitable dosage forms in the modernized world. Thus, here we describe different classes of biological therapeutic, with an emphasis on molecular properties, formulation challenges, and development strategies. We also present statistics on the different classes of approved biologic drugs and dosage forms.
Reference Key
muralidhara2020criticaldrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Muralidhara, Bilikallahalli K;Wong, Marcus;
Journal Drug discovery today
Year 2020
DOI
S1359-6446(20)30002-7
URL
Keywords
blood pressure heart rate exercise cardiac rehabilitation cardiovascular diseases. virtual reality exposure therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.